Molecular detection of hrHPV-induced high-grade squamous intraepithelial lesions of the cervix through a targeted RNA next generation sequencing assay

Julia Faillace Thiesen , Elise Jacquemet , Pascal Campagne, Denis Chatelain, Etienne Brochot, Yves‑Edouard Herpe , Nolwenn M. Dheilly , Fabrice Bouilloux, Bénédicte Rognon, Alexandre Douablin, Guillaume Leboucher , Florent Percher, Marc Eloit and Philippe Pérot Abstract Background Cervical cancer screening programs are increasingly relying on sensitive molecular approaches as primary tests to detect high‑risk

Molecular detection of hrHPV-induced high-grade squamous intraepithelial lesions of the cervix through a targeted RNA next generation sequencing assay Read More »

ABL Diagnostics Signs Exclusive Distribution Agreement with Riken Genesis to Expand Microbiology Genotyping in Japan

ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed leader in molecular diagnostics, is pleased to announce an exclusive distribution agreement with Riken Genesis Co., Ltd. (https://www.rikengenesis.jp/en.html). Under this partnership, Riken Genesis will promote and commercialize ABLD’s DeepChek® and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio. Through this collaboration, Riken Genesis

ABL Diagnostics Signs Exclusive Distribution Agreement with Riken Genesis to Expand Microbiology Genotyping in Japan Read More »

AdvancedDx Biological Laboratories USA Inc. and Complete Genomics LLC to co-market NGS microbiology solution in the U.S.

NEWBURYPORT, MA, UNITED STATES, September 23, 2024 /EINPresswire.com/ — AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, is pleased to announce today the execution of a co-marketing agreement to co-promote in the USA Next Generation

AdvancedDx Biological Laboratories USA Inc. and Complete Genomics LLC to co-market NGS microbiology solution in the U.S. Read More »

https://pubmed.ncbi.nlm.nih.gov/39185639/

The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting Alizée Foury 1 2, Aline Saunier 2, Audrey Taverniers 2, Nathalie Pinet 2, Thomas Josse 2, Eliette Jeanmaire 3, Caroline Emilie 3, Evelyne Schvoerer 2 4, Cédric Hartard 2 4 Abstract Improving the therapeutic management of HIV-positive persons is a major public health issue and includes better detection of drug resistance mutations (DRMs). The aim of this study was

https://pubmed.ncbi.nlm.nih.gov/39185639/ Read More »

ABL Diagnostics continues its surveillance of SARS-CoV-2 variants and prepares for any resurgence of COVID-19 outbreaks

WOIPPY, FRANCE, August 21, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories today announced its DeepChek® offer for SARS-CoV-2 Assays & Software, able to identify, to distinguish and to monitor circulating SARS-CoV-2 variants, indicative of COVID-19 infection and related epidemics, has

ABL Diagnostics continues its surveillance of SARS-CoV-2 variants and prepares for any resurgence of COVID-19 outbreaks Read More »

ABL Diagnostics expands its network of exclusive distributors and appoints INTERLUX OÜ in Estonia

WOIPPY, FRANCE, July 16, 2024 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – ABLD, the “Company”), a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories is pleased to announce today the execution of an exclusive distribution agreement to confer to Interlux OÜ (https://www.linkedin.com/company/interlux-estonia/ ) the rights to promote and commercialize ABLD assays and software

ABL Diagnostics expands its network of exclusive distributors and appoints INTERLUX OÜ in Estonia Read More »

Scroll to Top